NCT04171414View on ClinicalTrials.gov

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

November 4, 2019

Study Completion Date

April 24, 2020

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CT-P17 SC AI (adalimumab)

Subcutaneous Injection of Adalimumab 40mg once every two weeks

Trial Locations (1)

Unknown

Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz

Sponsors

Lead Sponsor

Celltrion

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Celltrion

INDUSTRY